Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification

Giorgio Bogani,Francesco Raspagliesi

DOI: https://doi.org/10.1001/jamaoncol.2024.3239

IF: 33.006

2024-10-19

JAMA Oncology

Abstract:To the Editor We have read with interest the article by Ciobanu and colleagues, which presented data concerning the underutilization and overutilization of radiotherapy in stage I endometrioid endometrial cancer based on molecular classification. We would like to raise 3 points for consideration. First, although molecular classification is widely used, it is important to note that prospective data validating its value are still lacking. Consequently, the terms "undertreatment" and "overtreatment" may be subject to misinterpretation. Second, according to available guidelines, no adjuvant treatment is recommended for p53 abnormal endometrial cancer without myometrial invasion. Conversely, for cases with myometrial invasion, the recommended treatment is chemotherapy in combination with radiotherapy or chemotherapy alone. We would like to inquire whether the analysis considered the presence of myometrial invasion and whether data regarding chemotherapy administration are available. Finally, radiotherapy functions as a local or locoregional treatment. Therefore, it would be valuable to report the rates of local and locoregional failure according to the administration of adjuvant radiotherapy and molecular classification. Such data could aid in identifying instances of underutilization or overutilization of radiotherapy.

oncology